Skip to content

Anteris Technologies Global

US · AVR #3553 by market cap Listed 2024
4.99 -0.10 -1.96%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 2.33 Cheap vs history 18th percentile
5-year average -614.00 · #63 of 127 in Medical Devices
P/E ratio -3.39 Cheap vs history 26th percentile
5-year average -2.69 · forward -6.52
P/S ratio 226.59 In line with history 59th percentile
5-year average 185.70 · forward 335.13 · #134 of 136 in Medical Devices

Vs. peers Medical Devices

Company Market cap P/E (TTM) P/B Div yield
Anteris Technologies Global (AVR) 486.49M -3.12 2.15 0.00%
Abbott Laboratories (ABT) 178.39B 38.29 3.50 2.41%
Medtronic (MDT) 127.84B 24.62 2.54 2.85%
Stryker Corp (SYK) 118.01B 33.01 5.03 1.14%
Boston Scientific (BSX) 60.85B 17.71 2.37 0.00%
Edwards Lifesciences (EW) 58.56B 57.54 5.39 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value10.06 Economic moatNone UncertaintyVery High

Trading 101.6% below Morningstar's fair value estimate.

Fair value

Anteris Technologies Global Corp is assigned a 4-star quantitative star rating, reflecting our opinion that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 46% discount to our quantitative fair value estimate of $10.06 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The firm's valuation metrics bolster our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's price to cash ratio of 2.2 lies in the bottom 30% compared with global peers. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. We believe this is a sign that shares could be undervalued.

On a different note, the company's unfavorable dividend structure is potentially concerning. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. The firm's forward dividend yield of 0%, for example, sits in the bottom 30% globally. This could imply a planned dividend cut or relatively high share price, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Anteris Technologies Global discussion 0 comments

Add a comment